Last Updated : June 29, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | ||
| Cymbalta | Duloxetine hydrochloride | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
| Cyramza | Ramucirumab | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cyramza | Ramucirumab | Cancelled | ||||
| Cystadrops | cysteamine | Corneal cystine crystal deposits | Reimburse with clinical criteria and/or conditions | Complete | ||
| Daklinza | daclatasvir | Hepatitis C, Chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Daklinza | Daclatasvir | Hepatitis C, Chronic | List with clinical criteria and/or conditions | Complete | ||
| Darzalex | Daratumumab | Multiple Myeloma | Do not reimburse | Complete | ||
| Darzalex | Daratumumab | Rd for MM | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | daratumumab | Light chain (AL) amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | Daratumumab | Multiple Myeloma (second-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Darzalex | Daratumumab | BMP for Multiple Myeloma (newly diagnosed) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Daurismo | Glasdegib | Acute Myeloid Leukemia (AML) | Do not reimburse | Complete | ||
| Daxas | Roflumilast | Chronic obstructive pulmonary disease | Do not list | Complete | ||
| Dayvigo | lemborexant | Insomnia | Do not reimburse | Complete | ||
| Delstrigo | doravirine lamuvidine tenofovir disoproxil fumarate | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Demylocan | decitabine | Myelodysplastic Syndromes | Unable to recommend reimbursement | Not filed | ||
| Denavir | Penciclovir | Herpes labialis (cold sores) | Do not list | Complete | ||
| Descovy | Emtricitabine /tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Diacomit | Stiripentol | Dravet Syndrome | List with criteria/condition | Complete | ||
| Dificid | Fidaxomicin | Clostridium difficile infection | Do not list at the submitted price | Complete | ||
| Dificid | fidaxomicin | Clostridium difficile infection | Active | |||
| Dojolvi | triheptanoin | Long-chain fatty acid oxidation disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
| Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Do not reimburse | Active |
Last Updated : June 29, 2024